维普中文期刊产品整合服务
4篇 您的检索式:作者名="Chenxing Cao"
    题名 作者 年代 出处 被引量
1QTL Mapping for Cucumber Fruit Size and Shape with Populations from Long and Round Fruited Inbred Lines显示文摘To gain insight into the molecular and genetic basis of fruit size and shape in cucumber,we conducted Quantitative Trait Locus(QTL)mapping with F2 and BC1F1 populations derived froma cross between the Northern-China type inbred line CNS21 and the Southern-China type inbred line RNS7.Populations were evaluated during two developmental stages,ovary at anthesis and commercial fruit(immature fruit).A total of 13 major-effect QTLs(R2>10%)were detected for six traits,and one of them,fruit shape index 2.1,explained more than 50%of phenotypic variation.All QTLs distributed on chromosome(chr)1 and 2.We constructed a physical map containing almost all of the QTLs with their physical location from previous studies.For fruit size and shape,the highest number of QTLs were mapped on chr1 and chr6,and the fewest number were mapped on chr2 and chr7.At least one consensus region was presented on each chromosome.In addition,three candidate genes were predicted between the long-fruited and round-fruited inbred lines by comparing the sequences of the consensus region of chr3,where many QTLs for marketable fruit length had been detected.Our results provide a base for additional QTLs and molecular markers for fruit size and shape in cucumber breeding.Zhihui Gao Haiyang Zhang Chenxing Cao Jing Han Hao Li Zhonghai Ren 2020Horticultural Plant Journal2020,6,3:7
2Synthesis of K 2 SiF 6: Mn 4+ Phosphor from SiO 2 Powders via Redox Reaction in HF / KMnO 4 Solution and Their Application in Warm‐White LED显示文摘Chenxing Liao Renping Cao Zhijun Ma Yang Li Guoping Dong Kaniyarakkal N. Sharafudeen Jianrong Qiu 2013J. Am. Ceram. Soc2013,,11:1
3Biomimetic nanomedicines for precise atherosclerosis theranostics显示文摘Atherosclerosis(AS)is a leading cause of the life-threatening cardiovascular disease(CVD),creating an urgent need for efficient,biocompatible therapeutics for diagnosis and treatment.Biomimetic nanomedicines(b NMs)are moving closer to fulfilling this need,pushing back the frontier of nano-based drug delivery systems design.This review seeks to outline how these nanomedicines(NMs)might work to diagnose and treat atherosclerosis,to trace the trajectory of their development to date and in the coming years,and to provide a foundation for further discussion about atherosclerotic theranostics.Ying Tao Xinmiao Lan Yang Zhang Chenxing Fu Lu Liu Feng Cao Weisheng Guo 2023Acta Pharmaceutica Sinica B2023,13,11:0
4PRMT2β suppresses autophagy and glycolysis pathway in human breast cancer MCF-7 cell lines显示文摘Autophagy as a novel therapeutic target can inhibit or increase treatment efficacy in various types of breast cancer in a cell-type-dependent manner [1,2].Several studies have revealed that the coordination between Akt and the glycolytic pathway plays an indispensable role in mediating autophagy and caspase-dependent apoptosis,suggesting that a new regulatory mechanism for the process [3,4].Protein arginine N-methyltransferases(PRMTs)are eukaryotic enzymes that catalyze the transfer of methyl groups from S-adenosylmethionine to arginine residues of numerous PRMT substrates [5,6].PRMT2(also known as HRMT1L1)belongs to the arginine methyltransferase family [7].PRMT2β is a novel PRMT2 splice variant isolated from breast cancer cell [8].It occurs at the 3′ end of the PRMT2,resulting in loss of exons 7–9 and downstream frame-shifting [9].PRMT2β possesses 83 new amino acids at the C-terminus and its size is 301 amino acids.Our previous study reported that PRMT2β has potential antitumor effect by suppressing cyclin D1 expression [10].However,little is known about whether PRMT2β could regulate autophagy and glycolysis of MCF-7 cells.Yajun Chenx Xianpeng Dai Yao Yao Jing Wang Xinzhi Yang Yunsheng Zhang Jing Yang Renxian Cao Gebo Wen Jing Zhong 2019Acta Biochimica et Biophysica Sinica2019,51,3:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费